BIIB080 (MAPTRx)

BIIB080 (MAPTRx)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">BIIB080 (MAPTRx)</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">ASO (gene silencing)</td>
<td>BIIB080, NIO752</td>
</tr>
<tr>
<td class="label">MTBR antibodies</td>
<td>Eilanetug, Bepranemab</td>
</tr>
<tr>
<td class="label">N-terminal antibodies</td>
<td>Gosuranemab, Tilavonemab</td>
</tr>
<tr>
<td class="label">Kinase inhibitors</td>
<td>Multiple programs</td>
</tr>
<tr>
<td class="label">Aggregation inhibitors</td>
<td>Multiple programs</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>BIIB080 (Biogen)</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Biogen/Ionis</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Dose tested</td>
<td>10-120 mg</td>
</tr>
<tr>
<td class="label">CSF tau reduction</td>
<td>50-60%</td>
</tr>
<tr>
<td class="label">FDA status</td>
<td>Fast Track</td>
</tr>
</table>

BIIB080 (MAPTRx)

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">BIIB080 (MAPTRx)</th>
</tr>
<tr>
<td class="label">Approach</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">ASO (gene silencing)</td>
<td>BIIB080, NIO752</td>
</tr>
<tr>
<td class="label">MTBR antibodies</td>
<td>Eilanetug, Bepranemab</td>
</tr>
<tr>
<td class="label">N-terminal antibodies</td>
<td>Gosuranemab, Tilavonemab</td>
</tr>
<tr>
<td class="label">Kinase inhibitors</td>
<td>Multiple programs</td>
</tr>
<tr>
<td class="label">Aggregation inhibitors</td>
<td>Multiple programs</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>BIIB080 (Biogen)</td>
</tr>
<tr>
<td class="label">Developer</td>
<td>Biogen/Ionis</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Dose tested</td>
<td>10-120 mg</td>
</tr>
<tr>
<td class="label">CSF tau reduction</td>
<td>50-60%</td>
</tr>
<tr>
<td class="label">FDA status</td>
<td>Fast Track</td>
</tr>
</table>

BIIB080 (development code MAPTRx, formerly IONIS-MAPTRx) is an antisense oligonucleotide (ASO) therapy developed by Biogen and Ionis Pharmaceuticals for the treatment of Alzheimer's disease and other tauopathies[@biib][@biib2022][@biiba]. It represents a novel gene-silencing approach that reduces tau protein production at the mRNA level, offering a fundamentally different mechanism from antibody-based tau immunotherapies.

The development of BIIB080 represents one of the most advanced clinical tests of the tau reduction hypothesis in humans. By directly targeting the genetic source of tau protein production, this ASO therapy addresses the root cause of tau pathology rather than attempting to clear tau after it has already accumulated. This approach has demonstrated unprecedented levels of tau reduction in human clinical trials, with CSF total tau reductions of up to 50-60% at the highest doses tested.

BIIB080 has received Fast Track designation from the U.S. Food and Drug Administration (FDA), highlighting its potential to address an unmet medical need in Alzheimer's disease and related tauopathies. The program has advanced through Phase I and Phase I/II studies and is now in active Phase II clinical development.

Molecular Mechanism and Design

Antisense Oligonucleotide Technology

BIIB080 leverages antisense oligonucleotide (ASO) technology to achieve gene silencing at the pre-translational level. ASOs are short, synthetic DNA-like molecules that bind to specific messenger RNA (mRNA) sequences through base-pairing, leading to degradation of the target mRNA and subsequent reduction in protein production.

The key aspects of BIIB080's molecular design include:

Gapmer Architecture:

• BIIB080 employs a gapmer design with a central deoxynucleotide "gap" flanked by modified nucleotide "wings"
• The gapmer structure is specifically optimized to recruit RNase H1 upon binding to target mRNA
• The 2'-O-methoxyethyl (2'-MOE) modifications on the flanking nucleotides provide enhanced nuclease resistance

• The ASO sequence is designed to be specific for the MAPT mRNA
• The binding site is selected to minimize off-target effects on other genes
• The target sequence is conserved across human MAPT splice variants

The RNase H1 mechanism offers several advantages for tau reduction:

Tau Isoform Targeting

The MAPT gene produces six alternative splicing isoforms in the adult human brain through different combinations of exons 2, 3, and 10. These isoforms are categorized as 3R (three repeat) and 4R (four repeat) tau, depending on whether they contain three or four microtubule-binding repeats. The balance between 3R and 4R tau is critical for normal neuronal function, and dysregulation of this balance is implicated in various tauopathies.

BIIB080 targets all tau isoforms because it binds to a region of the mRNA that is common to all splice variants[@muller2024]. This comprehensive targeting ensures reduction of total tau burden regardless of which isoform is predominating in a particular disease context. This is particularly important in Alzheimer's disease, where both 3R and 4R tau form neurofibrillary tangles, and in 4R-predominant tauopathies like PSP and CBD.

Clinical Development

Phase I Trial (NCT03119818)

The first-in-human study of BIIB080 established the safety, tolerability, and pharmacokinetics of this ASO in both healthy volunteers and patients with mild Alzheimer's disease[@biib2022]:

Study Design:

• Single ascending dose study in healthy volunteers
• Multiple ascending dose study in patients with mild AD
• Intrathecal administration (lumbar puncture)
• Dose range: 2 mg to 120 mg

• Dose-dependent reduction in CSF total tau (up to 50-60% reduction at highest doses)
• Dose-dependent reduction in CSF phosphorylated tau species (p-tau181)
• Acceptable safety profile at all dose levels
• No dose-limiting toxicities identified

Phase I/II Trial in Alzheimer's Disease (NCT04784160)

A subsequent Phase 1/2 study further evaluated BIIB080 in patients with mild Alzheimer's disease[@biiba]:

Study Design:

• Randomized, placebo-controlled, double-blind
• Multiple dose cohorts
• 12-month treatment period with extended follow-up

• Sustained dose-dependent reductions in CSF total tau
• Effects maintained over extended treatment period
• Validated the ASO approach for tau reduction
• Consistent safety profile with Phase I

Phase II Trial in Alzheimer's Disease (NCT05399888)

BIIB080 advanced to a pivotal Phase II trial for Alzheimer's disease[@biib]:

Study Details:

• Status: Active/recruiting, expected completion May 2026
• Indication: Early Alzheimer's disease
• Enrollment: 416 participants
• Design: Randomized, placebo-controlled, double-blind

• Safety and tolerability
• Change in CSF total tau at 12 months
• Change in cognitive endpoints

• CSF phosphorylated tau (p-tau181, p-tau217)
• Tau PET imaging using [^18F]flortaucipir
• Plasma biomarkers
• Cognitive measures (ADAS-Cog13, CDR, MMSE)

2026 Exploratory Clinical Outcome Results

New exploratory analyses from the Phase 1b long-term extension study were published in Nature Aging (February 2026)[@nataging2026]. This analysis examined clinical outcomes in participants with mild Alzheimer's disease who received high-dose BIIB080 (60 mg or 115 mg) during the open-label extension.

Key Findings:

• Cognitive Benefit: Consistent trend of slowed decline on cognitive, functional, and global measures favoring BIIB080 high-dose groups
• Tau PET Reduction: Reductions from baseline in brain neurofibrillary tangles measured with tau PET supported these clinical trends
• Assessments: Clinical outcomes measured via CDR (Clinical Dementia Rating), MMSE (Mini-Mental State Examination), FAQ (Functional Activities Questionnaire), and RBANS (Repeatable Battery for the Assessment of Neuropsychological Status)

The Phase II trial (NCT05399888) in early Alzheimer's disease is expected to complete in May 2026, which will provide more robust efficacy data.

Phase I Trial in Frontotemporal Dementia

BIIB080 has also been evaluated in frontotemporal dementia (FTD) with tau pathology[@biibb]:

Study Details:

• Status: Completed
• Publication: Results published in Nature Medicine (2023)
• Indication: FTD with tau pathology

• Demonstrated target engagement in FTD patients
• CSF tau reduction similar to AD studies
• Safety profile consistent with other studies
• Provides proof-of-concept for ASO approach in non-AD tauopathies

Biomarker Strategy

Clinical trials for BIIB080 utilize comprehensive biomarker approaches to demonstrate target engagement and predict clinical outcomes[@lane2023][@taylor2023]:

Primary Pharmacodynamic Biomarkers

Cerebrospinal Fluid Total Tau:

• Direct measurement of tau protein in cerebrospinal fluid
• Primary pharmacodynamic biomarker for BIIB080
• Demonstrates dose-dependent reduction up to 50-60%

• Measurement of phosphorylated tau species (p-tau181, p-tau217)
• More specific markers of pathological tau
• Also reduced in a dose-dependent manner

Secondary Biomarkers

Tau PET Imaging:

• [^18F]flortaucipir to assess regional tau burden
• Measures neurofibrillary tangle burden in the brain
• Can demonstrate tau reduction in brain tissue
• Provides spatial resolution that CSF biomarkers cannot

• Emerging plasma p-tau assays as less invasive markers
• p-tau217 and p-tau181 show promise as blood-based markers
• Enable more frequent monitoring than CSF sampling
• Correlation with CSF biomarkers being established

• Neurofilament light chain (NfL) as marker of neuroaxonal injury
• Brain volume measurements (MRI)
• May serve as downstream markers of treatment effect

Biomarker-Guided Dosing

The biomarker strategy allows for dose optimization based on target engagement[@taylor2023]:

• CSF tau reduction serves as a proxy for brain tau reduction
• Dose selection can be guided by achieving optimal tau reduction
• Monitoring enables early detection of treatment response
• Biomarker trajectories may predict clinical outcomes

Therapeutic Rationale

The Tau Hypothesis

The development of BIIB080 is grounded in the tau hypothesis, which posits that tau protein aggregation and spread drives neurotoxicity in Alzheimer's disease and related tauopathies[@smith2023]. This hypothesis is supported by:

Gene Silencing vs. Antibody Clearance

BIIB080's ASO approach differs fundamentally from antibody-based immunotherapies:

Antibody Approach:

• Target extracellular tau after it's produced
• Limited blood-brain barrier penetration
• Clear tau after it has accumulated
• Depend on peripheral clearance mechanisms

• Target tau production at the source (mRNA in neurons)
• Direct CNS delivery via intrathecal administration
• Prevent tau from being produced
• Reduce all tau species including intracellular tau

Therapeutic Window

An important consideration is the therapeutic window between pathological tau reduction and disruption of normal tau function. Preclinical studies have established that partial tau reduction (50-60%) is well-tolerated and provides neuroprotection in mouse models[@lee2024]. This aligns with the target engagement seen in BIIB080 clinical trials, where similar levels of CSF tau reduction were achieved without concerning safety signals.

Safety Profile

Observed Safety Data

BIIB080 has demonstrated an acceptable safety profile across multiple clinical trials:

Common Adverse Events:

• Injection site reactions (common with intrathecal delivery)
• Headache (expected with lumbar puncture)
• Back pain
• Mild CSF pleocytosis (transient)

• No serious adverse events attributed to BIIB080
• No dose-limiting toxicities identified
• No significant safety signals in any trial

• Regular neurological examinations
• CSF cell count and chemistry monitoring
• Platelet counts
• Liver function tests

Comparison to Other ASO Programs

The safety profile is consistent with other CNS-targeting ASOs in development. The intrathecal route has been used safely in multiple clinical programs, and the ASO chemistry has been refined over decades of development to minimize immunogenicity and off-target effects.

Competitive Landscape

Tau-Targeting Therapies

BIIB080 competes with multiple tau-targeting therapeutic approaches:

Comparison to NIO752

BIIB080 is similar to Roche's NIO752 (RG6100), another MAPT-targeting ASO in Phase II development:

Both programs use similar ASO chemistry and target the same gene, representing a competitive but complementary approach to tau reduction.

Pharmacokinetics and Distribution

Intrathecal Delivery

BIIB080 is administered via intrathecal injection, which delivers the ASO directly into the cerebrospinal fluid (CSF) space[@johnson2022]. This route is necessary because systemically administered ASOs do not efficiently cross the blood-brain barrier.

Key aspects of intrathecal delivery include:

• Bypassing the blood-brain barrier: Direct CSF administration avoids the need for CNS uptake from the periphery
• Distribution: ASOs in CSF distribute throughout the central nervous system via CSF flow
• Tissue penetration: ASOs enter brain tissue from the CSF, reaching neurons and other CNS cell types
• Dosing frequency: The half-life of ASOs in CNS tissue supports monthly or less frequent dosing

Dose-Response Relationship

The clinical trials have established a clear dose-response relationship:

• Low doses (2-10 mg): Minimal CSF tau reduction
• Medium doses (20-40 mg): Moderate CSF tau reduction (20-40%)
• High doses (60-120 mg): Robust CSF tau reduction (50-60%)

Future Development

Unanswered Questions

Several critical questions remain to be answered:

Potential Development Pathways

Success in the Phase II trial could enable multiple development pathways:

Long-Term Vision

BIIB080 represents one of the most advanced tests of the tau reduction hypothesis. If successful, it would validate the ASO approach for neurodegenerative disease and potentially transform treatment of Alzheimer's disease and related disorders.

The demonstration of both biomarker reduction and preliminary clinical benefit in the 2026 exploratory analysis provides encouraging evidence that tau reduction can achieve disease modification. The upcoming Phase II results will provide more definitive evidence on the clinical potential of this approach.

Conclusion

BIIB080 (MAPTRx) is a highly advanced antisense oligonucleotide therapeutic targeting the MAPT gene for tau reduction in Alzheimer's disease and other tauopathies. Through its novel gene-silencing mechanism, it offers a fundamentally different approach from antibody-based immunotherapies that have previously failed in clinical trials.

The program has demonstrated:

• Unprecedented levels of tau reduction in human clinical trials (50-60%)
• Acceptable safety profile across multiple studies
• Preliminary evidence of clinical benefit in exploratory analyses
• Potential applicability across multiple tauopathies

Pathway Diagram

References